Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01617668 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 209
- Enrollment target
NCT01617668 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 209 participants.
The verdict
NCT01617668, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 209 participants
- Enrollment target
Study Summary
To assess whether adding LCL161 to weekly paclitaxel enhances the efficacy of paclitaxel in women with triple negative breast cancer whose tumors are positive for a defined pattern of gene expression
Interventions
- DRUG paclitaxel
- DRUG LCL161
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01617668
The ClinicalTrials.gov registry entry for NCT01617668 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel is the first listed.
NCT01617668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01617668 about?
NCT01617668 is a clinical study titled "A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer". To assess whether adding LCL161 to weekly paclitaxel enhances the efficacy of paclitaxel in women with triple negative breast cancer whose tumors are positive for a defined pattern of gene expression
What is the current status of trial NCT01617668?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 209 participants. The study started on 2012-08. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01617668?
The interventions under investigation include: paclitaxel (DRUG), LCL161 (DRUG).
Who is sponsoring clinical trial NCT01617668?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.